CATEGORIES: Research

New Registry Helps Researchers Find A Cure: Q & A with CEO Kyle Brown, Crossroads

by | Jun 25, 2013 | 0 comments

Q & A with CEO Kyle Brown, Crossroads

New Registry Helps Researchers Find A Cure

The Hereditary Neuropathy Foundation (HNF) and Hannah’s Hope Fund (HHF) are excited about their partnership to co-fund the Global  Registry for Inherited Neuropathies.  According to the Global Rare Diseases Patient Registry and Data Repository (GRDR), rare diseases (6,500 disorders each occurring in fewer than 200,000 persons in the USA) are so uncommon that no single institution has sufficient numbers of patients to conduct clinical and translational research.  Identifying patients and gathering information for many rare diseases is labor intensive and expensive. The GRDR allows any rare disease population, regardless of size, to collect patient data that can identify clinical trial candidates for research. By assembling many small patient registries into a common data repository, researchers will have the ability to look beyond a single gene/indication which may reveal associations between genes and diseases.

We asked Kyle Brown, CEO of Patient Crossroads Registry Network of California, to answer some questions about the benefit of a registry to CMT patients.  Patient Crossroads is working to collect de-identified patient information for clinical research for the GRDR.

Why do we need a registry? 

There is a huge reason to have a registry.  How can you expect investments of millions of dollars without information? Raising visibility of any disorder to doctors and scientists is essential.  For one thing, it encourages areas of research for scientists to go into.  Raising awareness and presenting a cohesive front creates a community.  It says “we are all willing to do whatever you need to help.  We are willing to participate.”

Is there a downside to having a registry?

Only that when there are multiple foundations and organizations for a particular disease, they compete for patient data for selfish gains , to show themselves as having their hearts in the right place, but in order to get results the information should be shared.  Unfortunately they see the information they have as a proprietary resource, belonging only to them.  Organizations need a wake-up call to share data.  Sharing should be rewarded. The Global Registry for Inherited Neuropathies will be shared!

Other than that, there isn’t a downside to having a registry.  All patient information is secure and kept private.

Why should groups invest their limited resources in creating a registry instead of funding research? 

It takes about $ 800,000,000 and approximately 12-14 years to develop a drug.  It is not a smooth process, and most research gets hung up at Stage Three, which is conducting clinical trials.   In order to test a drug you need enough people with the disease willing to participate in the trials.  When a disease is rare or unknown, such as CMT, it is that much more difficult to assemble enough people for a trial.  The registry will give researchers access to a significantly larger population of potential participants and that would speed up the process.

What else should we do to move toward treatments and a cure?

Get involved! Organize the patient community. Make your information available to researchers.  Be willing to participate in clinical studies.  Register by taking a short ½ hour – 45 minute medical questionnaire for the registry.  I realize some people have survey fatigue.  They think, “How many times am I going to be asked the same questions?” But having that information will be a huge asset for research on a global level.

Can you give an example of how?

It’s about numbers.  The more people in need of a treatment or cure the greater the chance of getting funding.  Additionally, if you can tie a rare disease to a common disease, which shares a lot of similarities, you can often find substantial funding for research.  If you are lucky there is some advantage to a person with the rare disease taking the same drug.

Right now, there are about 20-30 million people listed on the Global Rare Registry and Data Repository. Why hold that information? Give it to the researchers, while keeping it private, to develop drugs we need. There are ethical ways to do what is right for the community and this is one of them.

555[1]

Learn more on this topic

Related Blog Posts

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news